Where can I buy the genuine drug Zenocutuzumab?

Zenocutuzumab (trade name: Bizengri) is an innovative bispecific monoclonal antibody drug developed by Merus, a Dutch biopharmaceutical company. The drug has received accelerated approval from the US FDA in 2024 and is mainly used to treat patients with advanced non-small cell lung cancer and pancreatic cancer carrying the NRG1 fusion gene. Since NRG1 fusion is a rare genetic mutation, the launch of this drug has brought new hope to some patients who have failed to respond to traditional treatments.

Currently, zetolizumab is only available in the United States. If patients want to obtain the drug, they must obtain a prescription from a local medical institution in the United States. The general process includes undergoing molecular genetic testing such as NGS to confirm the presence of NRG1 fusion mutations, and then a doctor with an oncology background will prescribe a medication plan. The drug is distributed through designated pharmacies or hospital pharmacy departments. The recommended dose is intravenous infusion treatment once every two weeks, and the duration needs to be determined based on the response to the condition.

Zetolizumab has not yet been approved for marketing in China, so local hospitals cannot directly prescribe and provide the drug. For patients who meet the conditions for medication, they can choose to go to the United States for medical treatment or arrange it through an agency with formal medical outbound resources. Some professional international medical service platforms provide remote consultation, prescription referral and cross-border transportation services to help patients obtain original drugs. However, the process is complicated and requires preparation of genetic reports, medical records and related translation documents in advance.
Since zetolizumab has not yet been approved in China, there may be so-called "purchasing agents" on the market through informal means, and the risk is high. It is recommended that patients must go through legal channels to avoid delays in treatment or adverse reactions due to drug authenticity issues. At the same time, the use of this drug must be under the guidance of a doctor, and accompanied by regular inspections of efficacy and side effects. Before considering taking medication, patients should undergo genetic screening to confirm whether they carry NRG1 fusion mutations to avoid ineffective treatment and waste of resources.
Reference: https://www.drugs.com/